Equillium, Inc. (EQ)
Largest Insider Buys in Sector
EQ Stock Price History Chart
EQ Stock Performance
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment …
Insider Activity of Equillium, Inc.
Over the last 12 months, insiders at Equillium, Inc. have bought $0 and sold $79,933 worth of Equillium, Inc. stock.
On average, over the past 5 years, insiders at Equillium, Inc. have bought $0 and sold $786,589 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Equillium, Inc.
| 2024-11-14 | Sale | Chief Financial Officer | 10,000 0.0286% | $0.70 | $7,000 | +1.37% | ||
| 2024-10-28 | Sale | Sr. Vice President and COO | 15,000 0.0481% | $1.25 | $18,750 | 0.00% | ||
| 2024-10-28 | Sale | Principal Accounting Officer | 2,835 0.0091% | $1.25 | $3,544 | +10.00% | ||
| 2024-10-25 | Sale | Principal Accounting Officer | 683 0.0022% | $1.25 | $854 | 0.00% | ||
| 2024-09-26 | Sale | Chief Financial Officer | 10,000 0.0286% | $0.81 | $8,100 | 0.00% | ||
| 2024-09-16 | Sale | Principal Accounting Officer | 38,806 0.1083% | $0.85 | $32,985 | -9.26% | ||
| 2024-07-16 | Sale | Chief Financial Officer | 10,000 0.0368% | $0.87 | $8,700 | -8.54% | ||
| 2022-08-29 | Sale | Chief Financial Officer | 7,000 0.0202% | $2.83 | $19,810 | -68.77% | ||
| 2022-06-06 | Sale | Chief Financial Officer | 5,000 0.0147% | $2.52 | $12,600 | -34.00% | ||
| 2022-04-04 | Sale | Chief Financial Officer | 8,000 0.0228% | $3.18 | $25,440 | -41.54% | ||
| 2021-12-01 | Sale | Chief Financial Officer | 5,000 0.0181% | $5.08 | $25,402 | -45.48% | ||
| 2021-11-16 | Sale | Sr. Vice President and COO | 11,434 0.0391% | $5.49 | $62,715 | -50.09% | ||
| 2021-10-06 | Sale | Chief Scientific Officer | 8,092 0.0282% | $7.01 | $56,706 | -54.17% | ||
| 2021-09-27 | Sale | Chief Financial Officer | 8,000 0.0271% | $6.74 | $53,924 | -51.85% | ||
| 2021-07-27 | Sale | Chief Financial Officer | 5,000 0.0167% | $5.72 | $28,585 | -32.45% | ||
| 2021-06-08 | Sale | Chief Scientific Officer | 10,495 0.0339% | $7.18 | $75,315 | -37.70% | ||
| 2021-06-07 | Sale | Chief Scientific Officer | 22,390 0.074% | $7.12 | $159,409 | -35.76% | ||
| 2021-06-04 | Sale | Chief Scientific Officer | 13,539 0.0471% | $7.01 | $94,846 | -30.52% | ||
| 2021-05-26 | Sale | Chief Financial Officer | 5,000 0.0171% | $6.50 | $32,484 | -20.92% | ||
| 2020-12-28 | Sale | Chief Scientific Officer | 25,000 0.1048% | $4.52 | $113,045 | +37.96% |
Institutional Investor Ownership
| The Vanguard Group | $1.94M | 2.39 | 841,948 | +0.6% | +$11,591.58 | <0.0001 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $1.3M | 1.6 | 562,278 | 0% | +$0 | 3.44 | |
| Renaissance Technologies | $483,000.00 | 0.59 | 209,200 | -39.8% | -$319,306.41 | <0.01 | |
| Geode Capital Management | $461,456.00 | 0.57 | 199,728 | +15.86% | +$63,169.25 | <0.0001 | |
| Acadian Asset Management | $249,000.00 | 0.31 | 108,691 | New | +$249,000.00 | <0.01 |